Key result
A pretreatment plasma renin activity level >0.65 ng/ml/h increased the odds for systolic blood pressure control during treatment with candesartan.
Why the study?
Does pretreatment plasma renin activity predict the blood pressure response to antihypertensive drugs in patients with hypertension?
Does pretreatment plasma renin activity predict the blood pressure response to antihypertensive drugs in patients with hypertension?
Answers are grounded in this paper and cite their sources.
Pretreatment plasma renin activity levels can predict the blood pressure response to renin-angiotensin system blockers, supporting a more individualized approach to antihypertensive therapy.
Within the past few months, an orally active renin inhibitor has entered the antihypertensive drug treatment market.1 Its release has been met with both fanfare and skepticism.2,3 Proponents hail it as the first new drug class to arrive in a decade, emphasizing that it might share the characteristic benefits of other drug classes that interrupt the renin–angiotensin–aldosterone system. Others question the need for additional anti-renin system drug classes because the merits of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and β-adrenergic receptor blockers (β-blockers) are so well established and are available at much lower cost.4 This debate merely skates the surface of a deeper issue: despite the availability of antihypertensive drugs with different pharmacologic actions, only about one-half of all treated patients have their blood pressure (BP) adequately controlled.5 In view of the high stakes associated with uncontrolled hypertension, how can the practitioner reliably select effective antihypertensive drug treatment for the individual patient? Do most patients really require two or more drugs to control hypertension? A satisfactory answer to this question has not been provided by government-sanctioned treatment guidelines (i.e., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) or by the pervasive, industry-sponsored drug treatment trials that have fueled them (e.g., Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial).5,6 The limitations of this mutually reinforcing process have been explored previously in the Journal and elsewhere.7 The pathophysiology of hypertension is heterogeneous and there is evidence that the efficacy of antihypertensive medication is predictably related to the pharmacologic targeting of the relevant pressor mechanism in each patient.8,9,10 Accordingly, those with an activated renin system (plasma renin activity (PRA) level ≥0.65 ng/ml/h) are most likely to have their BP reduced when treated with a drug that interrupts this system (e.g., an ACE inhibitor, ARB, β-blocker and, presumably, a renin inhibitor) than with other drug classes.11 Conversely, those with predominantly sodium-volume dependent hypertension, identified by a low PRA level (PRA < 0.65 ng/ml/h), are most effectively treated by diuretics, calcium channel blockers and α1-adrenergic receptor blockers. When these individual patterns are not recognized, BP is less likely to be controlled by single-drug treatment.12 Consequently, as multiple drugs are added, both the risk of side effects and the cost of treatment increase. In this issue of the Journal, two studies explore possible predictors of antihypertensive efficacy of ARBs. Minami et al. report that treatment with the ARB, telmisartan, significantly decreased mean 24-h ambulatory BP in 11 consecutive Japanese subjects evaluated during an 8-week period.13 However, telmisartan-mediated reductions in casual office BP measurements and by ambulatory monitoring (i.e., 24-h, daytime, nighttime periods) were significantly less in those subjects with low pretreatment PRA levels (<0.65 ng/ml/h) than in those with higher PRA levels. The magnitude of reduction in BP level was significantly correlated with the pretreatment PRA level, but was independent of the pretreatment BP level. By incorporating ambulatory BP measurements in the analysis, this report extends earlier observations that have identified the pretreatment PRA level as a predictor of BP responsiveness to antihypertensive drugs that block the renin system.8,9,10 The small number of subjects required underscores the power of this relationship. The limitations of the study by Minami et al. include the relatively short follow-up period, the lack of information regarding blinding of the investigators to the PRA levels, and the possibility of error related to the small number of subjects evaluated.13 These limitations were absent in the study by Canzanello et al., in which casual office BP measurements were employed to evaluate the antihypertensive efficacy of candesartan during a 6-week treatment period in >400 African–American and non-Hispanic white subjects.14 The diastolic BP was required to be at least 90 mm Hg following a 4–6 week washout from previous drug treatment. Ethnicity–gender strata was significantly, but modestly associated with BP response to candesartan. Accordingly, systolic BP decreased to a greater extent in non-Hispanic white women, whereas diastolic BP fell more in non-Hispanic whites regardless of gender. The authors emphasize that these differences were not consistently observed in previous studies and, thus, do not reliably inform the clinician regarding selection of the most effective drug for the individual patient. Canzanello et al. importantly found that PRA accounted for a significant increase in predictability of systolic BP and diastolic BP reductions during treatment with candesartan.14 Of potential practical significance to the clinician is the finding that, after adjusting for other relevant variables, a pretreatment PRA level >0.65 ng/ml/h significantly increased the odds for systolic BP control (odds ratio 2.74; P < 0.04) and for diastolic BP control (odds ratio 3.22; P < 0.03) by candesartan. These observations may explain a significant component of the ethnic differences in BP response, as the median pretreatment PRA was significantly higher, and the candesartan-mediated BP reduction was greater in non-Hispanic whites than in African Americans. These findings reinforce the considerable body of evidence that drugs that interrupt the renin–angiotensin system (i.e., β-blockers, ACE inhibitors, ARBs) are likely to reduce BP more effectively in patients with pretreatment PRA levels that are at least 0.65 ng/ml/h. Moreover, these observations complement earlier findings that diuretic treatment is more likely than anti-renin drug therapy to lower BP in subjects with a pretreatment PRA below this level.8,9,10,15 Given that ARBs specifically block the renin–angiotensin system and that the demographic differences in PRA are relatively small and are not sufficient to predict renin status, it seems more reasonable to measure PRA levels directly rather than to rely on ethnicity–gender or other characteristics when deciding whether to select a drug that blocks the renin system.16 Canzanello et al. also report that the increase in the PRA level during treatment with candesartan significantly, albeit modestly improved the ability to predict treatment-related systolic and diastolic BP reductions.14 However, an important limitation in the design of their study may have weakened this association. They obtained blood samples for PRA measurement between 1 and 2 h after candesartan dosing. This time point does not represent the peak drug level, which occurs 3–4 h after dosing, thus it may underestimate the maximum treatment-induced rise in PRA, potentially obscuring a more robust association with the decrement in BP. In summary, these reports by Minami et al. and by Canzanello et al. each provide support for the concept that hypertension is a pathophysiologically heterogeneous condition in which renin–angiotensin system activity is an important determinant of the BP response to antihypertensive drug treatment.13,14 In these studies, the pretreatment PRA level was a significant predictor of treatment efficacy despite the different experimental designs employed and the ethnically diverse populations evaluated. These observations support the case that pathophysiologic markers such as PRA should be incorporated into the design of studies that assess antihypertensive treatment strategies. Dr. Blumenfeld is the recipient of research support by Otsuka Maryland Medicinal Laboratories for the study of a vasopressin receptor antagonist for the treatment of autosomal dominant polycystic kidney disease. This publication was made possible by the Rockefeller University CCTS, grant no. UL1 RR024143-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
No takes yet. Share an insight, caveat, or question.
Jon D. Blumenfeld (2007) conducted an editorial in Hypertension. Pretreatment plasma renin activity (PRA) ≥0.65 ng/ml/h vs. Pretreatment PRA <0.65 ng/ml/h was evaluated on Systolic blood pressure control (OR 2.74, p=<0.04). A pretreatment plasma renin activity level >0.65 ng/ml/h increased the odds for systolic blood pressure control during treatment with candesartan.
Synapse has enriched 10 related papers. Consider them for comparative context: